Cargando…

Association of Multi-Phasic MR-Based Radiomic and Dosimetric Features with Treatment Response in Unresectable Hepatocellular Carcinoma Patients following Novel Sequential TACE-SBRT-Immunotherapy

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is one of the most prevalent and devastating malignancies worldwide. An ongoing phase-II clinical trial assesses the efficacy of a novel sequential trans-arterial chemoembolization (TACE) plus stereotactic body radiotherapy (SBRT) plus immunotherapy str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Lok-Man, Lam, Sai-Kit, Zhang, Jiang, Chiang, Chi-Leung, Chan, Albert Chi-Yan, Cai, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954441/ https://www.ncbi.nlm.nih.gov/pubmed/36831445 http://dx.doi.org/10.3390/cancers15041105

Ejemplares similares

Dosimetric analysis of MR‐LINAC treatment plans for salvage spine SBRT re‐irradiation
por: Han, Eun Young, et al.
Publicado: (2022)

Evaluation of dosimetric uncertainty caused by MR geometric distortion in MRI‐based liver SBRT treatment planning
por: Han, Silu, et al.
Publicado: (2019)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Dosimetric Analysis of Microscopic Disease in SBRT for Lung Cancers
por: Mao, Ronghu, et al.
Publicado: (2017)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Dosimetric accuracy of delivering SBRT using dynamic arcs on Cyberknife
por: Bedford, James L., et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
por: Stauder, Michael C., et al.
Publicado: (2010)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
por: Bettinger, Dominik, et al.
Publicado: (2018)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

MR‐linac is the best modality for lung SBRT
por: Godley, Andrew, et al.
Publicado: (2019)

Lung SBRT: dosimetric and delivery comparison of RapidArc, TomoTherapy, and IMRT
por: Weyh, Ashleigh, et al.
Publicado: (2013)

A dosimetric analysis of a spine SBRT specific treatment planning system
por: Saenz, Daniel L., et al.
Publicado: (2018)

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma
por: Huang, Dexiao, et al.
Publicado: (2017)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma
por: Gurka, Marie K., et al.
Publicado: (2017)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Dosimetric impact of orthopedic metal artifact reduction (O‐MAR) on spine SBRT patients
por: Shen, Zhilei Liu, et al.
Publicado: (2015)

Dosimetric assessment of patient‐specific breath‐hold reproducibility on liver motion for SBRT planning
por: Lu, Lan, et al.
Publicado: (2020)

Which Is Better for Liver SBRT: Dosimetric Comparison Between DCAT and VMAT for Liver Tumors
por: Moon, Young Min, et al.
Publicado: (2020)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023)

SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience
por: Tozzi, Angelo, et al.
Publicado: (2013)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
por: Chen, Yongbiao, et al.
Publicado: (2023)

Online dosimetric evaluation of larynx SBRT: A pilot study to assess the necessity of adaptive replanning
por: Mao, Weihua, et al.
Publicado: (2016)

Stereotactic body radiation therapy (SBRT) and respiratory gating in lung cancer: dosimetric and radiobiological considerations
por: Herman, Tania De La Fuente, et al.
Publicado: (2010)

Is High Definition MLC Dosimetrically Superior to Standard Definition MLC for SIB-SBRT for Carcinoma Prostate
por: K, Bijina T, et al.
Publicado: (2019)

SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study
por: Serra, Marcello, et al.
Publicado: (2022)

The dosimetric impact of titanium implants in spinal SBRT using four commercial treatment planning algorithms
por: Liu, Chieh‐Wen, et al.
Publicado: (2023)

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
por: Qu, Shuping, et al.
Publicado: (2022)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
por: Yin, Liang, et al.
Publicado: (2023)

Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
por: Ayyub, Javaria, et al.
Publicado: (2023)

Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
por: Wu, Ying, et al.
Publicado: (2020)

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Junguo, et al.
Publicado: (2022)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

A comprehensive dosimetric study on switching from a Type-B to a Type-C dose algorithm for modern lung SBRT
por: Zhou, Christina, et al.
Publicado: (2017)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
por: Li, Shuqun, et al.
Publicado: (2023)

Dosimetric Effects of Differences in Multi-Leaf Collimator Speed on SBRT-VMAT for Central Lung Cancer Patients
por: Saito, Masahide, et al.
Publicado: (2022)

Dosimetric Impact of Intrafraction Prostate Motion and Interfraction Anatomical Changes in Dose-Escalated Linac-Based SBRT
por: Faccenda, Valeria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gqvtf5cad53bk421t9ppmj8rhh